Your browser doesn't support javascript.
loading
Renoprotective Effect of Pitavastatin against TAA-Induced Renal Injury: Involvement of the miR-93/PTEN/AKT/mTOR Pathway.
Elbaset, Marawan A; Mohamed, Bassim M S A; Moustafa, Passant E; Esatbeyoglu, Tuba; Afifi, Sherif M; Hessin, Alyaa F; Abdelrahman, Sahar S; Fayed, Hany M.
Afiliação
  • Elbaset MA; Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
  • Mohamed BMSA; Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
  • Moustafa PE; Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
  • Esatbeyoglu T; Department of Molecular Food Chemistry and Food Development, Institute of Food Science and Human Nutrition, Gottfried Wilhelm Leibniz University Hannover, Am Kleinen Felde 30, Hannover 30167, Germany.
  • Afifi SM; Pharmacognosy Department, Faculty of Pharmacy, University of Sadat City, Sadat City 32897, Egypt.
  • Hessin AF; Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
  • Abdelrahman SS; Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
  • Fayed HM; Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
Adv Pharmacol Pharm Sci ; 2024: 6681873, 2024.
Article em En | MEDLINE | ID: mdl-38293706
ABSTRACT
This research investigated if pitavastatin (Pita) might protect rats' kidneys against thioacetamide (TAA). By altering the PTEN/AKT/mTOR pathway, pitavastatin may boost kidney antioxidant capacity and minimize oxidative damage. Statins have several benefits, including antioxidant and anti-inflammatory characteristics. The principal hypothesis of this study was that Pita can regulate the miR-93/PTEN/AKT/mTOR pathways, which is thought to be responsible for its renoprotective effects. The experiment divided male rats into four groups. Group 1 included untreated rats as the control. Group 2 included rats which received TAA (100 mg/kg intraperitoneally thrice a week for two weeks) to destroy their kidneys. Groups 3 and 4 included rats which received Pita orally at 0.4 and 0.8 mg/kg for 14 days after TAA injections. Renal injury increased BUN, creatinine, and MDA levels and decreased glutathione (GSH) levels. Pitavastatin prevented these alterations. TAA decreased PTEN and increased miR-93, Akt, p-Akt, mTOR, and Stat3 in the kidneys. Pitavastatin also regulated the associated culprit pathway, miR-93/PTEN/Akt/mTOR. In addition, TAA induced adverse effects on the kidney tissue, which were significantly ameliorated by pitavastatin treatment. The findings suggest that pitavastatin can attenuate renal injury, likely by regulating the miR-93/PTEN/Akt/mTOR pathway. This modulation of the pathway appears to contribute to the protective effects of pitavastatin against TAA-induced renal injury, adding to the growing evidence of the pleiotropic benefits of statins in renal health.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Adv Pharmacol Pharm Sci Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Egito

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Adv Pharmacol Pharm Sci Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Egito